Search

Your search keyword '"Dalbavancin"' showing total 1,476 results

Search Constraints

Start Over You searched for: Descriptor "Dalbavancin" Remove constraint Descriptor: "Dalbavancin"
1,476 results on '"Dalbavancin"'

Search Results

6. A comprehensive study on the identification and characterization of degradation products of lipoglycopeptide Dalbavancin using LC and LC‐HRMS/MS.

7. Unraveling novel mutation patterns and morphological variations in two dalbavancin-resistant MRSA strains in Austria using whole genome sequencing and transmission electron microscopy.

8. Unraveling novel mutation patterns and morphological variations in two dalbavancin-resistant MRSA strains in Austria using whole genome sequencing and transmission electron microscopy

9. Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry

10. Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin

11. Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series

13. Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.

14. Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience.

15. In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry.

16. In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital.

17. Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature.

18. Simulated Target Attainment of Multidose Regimens of Dalbavancin for Prolonged Durations of Therapy.

19. Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections.

24. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study

25. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study

27. Recurrent bacteremia and endocarditis due to Staphylococcus capitis in a patient with Bowen's disease: a case report.

28. Chronic antibiotic suppressive therapy with dalbavancin: a case series.

29. Real-World Dalbavancin Use for Serious Gram-Positive Infections: Comparing Outcomes Between People Who Use and Do Not Use Drugs.

30. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.

31. Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience.

32. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.

33. New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.

34. Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network

36. The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI

38. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis

39. When surgical option is not provided: a successful multidisciplinary approach to a refractory case of sternal osteomyelitis following coronary surgery.

40. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis.

41. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.

42. New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections.

43. Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.

44. Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?

45. Efficacy of Novel Antimicrobial Therapies for Treating Staphylococcus Infections in Wistar Rats.

46. New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.

47. Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections.

48. Complex Outpatient Antimicrobial Therapy: Alternative Management Strategies and Outcomes.

Catalog

Books, media, physical & digital resources